Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AVLN · NASDAQ · Pharmaceutical Preparations · No 10-K yet
Avalyn Pharma (AVLN) · oqro.io/stocks/AVLN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Avalyn Pharma is on record in SEC filings since 2006.
Since 2026, Avalyn Pharma insiders reported 0 open-market purchases and 4 sales on Forms 4 and 5.
In the last 90 days, 1 insider of Avalyn Pharma (AVLN) reported 4 open-market sales worth $6.7M in total on SEC Form 4. The largest seller by value was FMR LLC, with $6.7M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Avalyn Pharma (AVLN) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$30.28−0.31 (−1.01%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
+2.7% (+$0.79) from Apr 30, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $29.49 on Apr 30, 2026 to $30.28 on Nov 13, 2026 (+2.7%). Disclosed in this range: 4 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 8 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Boston, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$1.34B
Short interest: 2.3M shares sold short (5.2% of shares outstanding), −2.2% vs the previous count, 5.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Avalyn Pharma: 1 insider sold $6.5M on the open market (2 sales combined) and 1 fund cut or exited a position in the latest available 13F filings. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
—
Free cash flow, last 12 months
−$26.3M
This quarter −$26.3M, a year earlier −$20.7M
Net cash
$249M
Debt $14.8M, cash $264M, at Jun 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.
Fund moves
From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Nov 9 – Nov 10, 2026 · largest single transaction ~$5.05MNot reported under a pre-arranged trading plan
Nov 9, 2026~$5.05M · 174K sh @ $29.06
DetailsOfficial recordNov 10, 2026~$1.45M · 48K sh @ $30.28
DetailsOfficial recordNov 10, 2026~$165K · 5,565 sh @ $29.56
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Nov 9, 2026~$40K · 1,339 sh @ $29.75
DetailsOfficial recordInsiders of Avalyn Pharma reported 0 open-market purchases and 4 sales since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $6.7M4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
0 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in idiopathic pulmonary fibrosis (ipf), pulmonary fibrosis, progressive pulmonary fibrosis. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Apr 30, 2026, AVLN is up 2.7% and the index fund is up 5.0%: 2 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much AVLN moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
On the public record for Avalyn Pharma over the 12 months to Nov 14, 2026: 3 clinical trials.